A Study of HRS9531 Versus Semaglutide Once Weekly as Add-on Therapy to Metformin Monotherapy or in Combination With SGLT2 Inhibitors in Participants With Type 2 Diabetes
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 884 participants.
Also called NCT06649344
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 884 participants
- Registry
-
NCT06649344
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT06649344. Randomized; no masking; primary purpose treatment. Start 2024-10-31 (actual); primary completion 2026-07-18 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of HRS9531 Versus Semaglutide Once Weekly as Add-on Therapy to Metformin Monotherapy or in Combination With SGLT2 Inhibitors in Participants With Type 2 Diabetes
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- HRS9531 Injection
- Intervention (Drug)
- Semaglutide Injection
- Lead sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
Record details
- Record id
cardio:ct-nct06649344- Content hash
5d9e5371d6e619c6220fb2b9145439118ffa7f9dcacb77e775a0cc7462f378f7